19,971 Shares in Moderna, Inc. (NASDAQ:MRNA) Acquired by Ariadne Wealth Management LP

Ariadne Wealth Management LP acquired a new position in Moderna, Inc. (NASDAQ:MRNA) during the second quarter, according to its most recent filing with the SEC. The firm acquired 19,971 shares of the company’s stock, valued at approximately $2,372,000. Moderna comprises approximately 1.3% of Ariadne Wealth Management LP’s holdings, making the stock its 16th biggest holding.

A number of other large investors have also recently made changes to their positions in the business. Granite Bay Wealth Management LLC purchased a new position in shares of Moderna in the 2nd quarter valued at approximately $524,000. Truist Financial Corp increased its holdings in shares of Moderna by 7.3% in the 2nd quarter. Truist Financial Corp now owns 18,657 shares of the company’s stock worth $2,216,000 after purchasing an additional 1,275 shares in the last quarter. Northwestern Mutual Wealth Management Co. increased its holdings in shares of Moderna by 11.9% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 11,932 shares of the company’s stock worth $1,417,000 after purchasing an additional 1,265 shares in the last quarter. Silver Lake Advisory LLC bought a new stake in shares of Moderna in the 2nd quarter worth $299,000. Finally, Nemes Rush Group LLC boosted its position in Moderna by 18.4% in the second quarter. Nemes Rush Group LLC now owns 9,172 shares of the company’s stock worth $1,089,000 after purchasing an additional 1,427 shares during the last quarter. 75.33% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. Needham & Company LLC reaffirmed a “hold” rating on shares of Moderna in a research report on Friday, September 13th. Evercore ISI reiterated an “in-line” rating and set a $120.00 target price on shares of Moderna in a research report on Thursday, June 27th. Jefferies Financial Group downgraded Moderna from a “buy” rating to a “hold” rating and lowered their target price for the company from $120.00 to $65.00 in a research report on Friday, September 13th. William Blair restated a “market perform” rating on shares of Moderna in a report on Thursday, June 27th. Finally, Deutsche Bank Aktiengesellschaft upgraded Moderna from a “sell” rating to a “hold” rating and reduced their target price for the stock from $85.00 to $80.00 in a research note on Wednesday, August 7th. Two research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Moderna has an average rating of “Hold” and an average target price of $100.44.

Insider Activity at Moderna

In other news, CFO James M. Mock sold 689 shares of the firm’s stock in a transaction that occurred on Monday, July 8th. The shares were sold at an average price of $118.24, for a total transaction of $81,467.36. Following the transaction, the chief financial officer now directly owns 7,269 shares of the company’s stock, valued at $859,486.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Moderna news, Director Noubar Afeyan sold 15,000 shares of the stock in a transaction that occurred on Wednesday, July 10th. The shares were sold at an average price of $117.08, for a total transaction of $1,756,200.00. Following the completion of the sale, the director now owns 2,269,015 shares of the company’s stock, valued at approximately $265,656,276.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO James M. Mock sold 689 shares of the firm’s stock in a transaction that occurred on Monday, July 8th. The stock was sold at an average price of $118.24, for a total transaction of $81,467.36. Following the sale, the chief financial officer now directly owns 7,269 shares of the company’s stock, valued at approximately $859,486.56. The disclosure for this sale can be found here. In the last ninety days, insiders sold 78,158 shares of company stock worth $9,259,012. Insiders own 15.70% of the company’s stock.

Moderna Stock Performance

NASDAQ:MRNA opened at $66.83 on Tuesday. Moderna, Inc. has a 1 year low of $62.55 and a 1 year high of $170.47. The firm has a 50 day moving average of $84.24 and a 200-day moving average of $109.48. The company has a current ratio of 4.09, a quick ratio of 3.92 and a debt-to-equity ratio of 0.05. The stock has a market capitalization of $25.61 billion, a P/E ratio of -4.26 and a beta of 1.67.

Moderna (NASDAQ:MRNA) last released its earnings results on Thursday, August 1st. The company reported ($3.33) EPS for the quarter, topping analysts’ consensus estimates of ($3.47) by $0.14. The firm had revenue of $241.00 million during the quarter, compared to analyst estimates of $128.41 million. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. The business’s quarterly revenue was down 29.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($3.62) EPS. As a group, sell-side analysts anticipate that Moderna, Inc. will post -9.86 EPS for the current fiscal year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.